{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:02:48Z","timestamp":1782781368886,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study was to re-evaluate fluoroquinolone (FQ) use in treatment by analyzing the consumption of FQ and the resistance levels of selected Gram\u2011negative bacilli, as well as <jats:italic>Neisseria gonorrhoeae<\/jats:italic> and <jats:italic>Mycobacterium tuberculosis complex<\/jats:italic> in EU\/EEA countries and in Poland between 2016 and 2021. Data from ECDC surveillance systems EARS-Net, Euro-GASP, and the European Tuberculosis Surveillance Network were included in the description of pathogen resistance. And the ESAC-Net project for determining FQ consumption. In over half of the EU\/EEA countries, the consumption of fluoroquinolones decreased in both the community sector and the hospital sector between 2016 and 2021. The prevalence of FQ-R <jats:italic>Escherichia coli<\/jats:italic>, <jats:italic>Klebsiella pneumoniae<\/jats:italic>, <jats:italic>Acinetobacter<\/jats:italic> spp., <jats:italic>Mycobacterium tuberculosis complex<\/jats:italic>, and <jats:italic>Neisseria gonorrhoeae<\/jats:italic> exceeded 20%. The prevalence of fluoroquinolone-resistant (FQ-R) <jats:italic>Pseudomonas aeruginosa<\/jats:italic> in EU\/EEA countries was less than 20% except for 2017. In most EU\/EEA countries, the use of FQ has reduced in last years, except for countries like Poland where FQ were an overused group of antibiotics in the treatment of various types of infections. Fluoroquinolones, as life-saving antibiotics in severe infections, should be withdrawn from empirical treatment in Poland and in countries with a high prevalence of FQ-R microorganisms.<\/jats:p>","DOI":"10.1007\/s00210-023-02622-2","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T11:01:56Z","timestamp":1690369316000},"page":"795-805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Re-evaluating the suitability of using fluoroquinolones in the treatment of infections in the context of FQ consumption and correlating changes to microorganism resistance levels in EU\/EEA countries between 2016 and 2021"],"prefix":"10.1007","volume":"397","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9946-7855","authenticated-orcid":false,"given":"Piotr","family":"Serwacki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4383-7380","authenticated-orcid":false,"given":"Mateusz","family":"Gajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6592-4680","authenticated-orcid":false,"given":"Wioletta","family":"\u015awi\u0105tek-Kwapniewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6712-0726","authenticated-orcid":false,"given":"Marta","family":"Wa\u0142aszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-076X","authenticated-orcid":false,"given":"Karolina","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0756-1639","authenticated-orcid":false,"given":"Jadwiga","family":"W\u00f3jkowska-Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"2622_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2673-5","author":"MAH Berrevoets","year":"2017","unstructured":"Berrevoets MAH, ten Oever J, Sprong T, van Hest RM, Groothuis I, van Heijl I, Schouten JA, Hulscher ME, Kullberg BJ (2017) Monitoring, documenting and reporting the quality of antibiotic use in the Netherlands: a pilot study to establish a national antimicrobial stewardship registry. BMC Infect Dis. https:\/\/doi.org\/10.1186\/s12879-017-2673-5","journal-title":"BMC Infect Dis"},{"key":"2622_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.medmal.2019.09.007","volume":"50","author":"F Binda","year":"2020","unstructured":"Binda F, Tebano G, Kallen MC, ten Oever J, Hulscher ME, Schouten JA, Pulcini C (2020) Nationwide survey of hospital antibiotic stewardship programs in France. Med Mal Infect 50:414\u2013422","journal-title":"Med Mal Infect"},{"key":"2622_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.eururo.2019.06.011","volume":"76","author":"G Bonkat","year":"2019","unstructured":"Bonkat G, Pilatz A, Wagenlehner F (2019) Time to adapt our practice? The European Commission has restricted the use of fluoroquinolones since March 2019. Eur Urol 76:273\u2013275","journal-title":"Eur Urol"},{"key":"2622_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2146\/ajhp120568","volume":"70","author":"DW Bratzler","year":"2013","unstructured":"Bratzler DW, Dellinger EP, Olsen KM, Berr\u00edos-Torres S, Bongiorno-Karcher R (2013) Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health-Syst Pharm 70:195\u2013283","journal-title":"Am J Health-Syst Pharm"},{"key":"2622_CR5","volume-title":"Core elements of hospital antibiotic stewardship programs","author":"CDC","year":"2019","unstructured":"CDC (2019) Core elements of hospital antibiotic stewardship programs. US Department of Health and Human Services, CDC, Atlanta, GA"},{"key":"2622_CR6","unstructured":"Centers for Disease Control and Prevention (2022) Emerging infections program, healthcare-associated infections-community interface surveillance report, Clostridioides difficile infection (CDI), 2020.\u00a0https:\/\/www.cdc.gov\/hai\/eip\/pdf\/cdiff\/2020-CDI-Report-H.pdf"},{"key":"2622_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1473-3099(16)30514-X","volume":"17","author":"KE Dingle","year":"2017","unstructured":"Dingle KE, Didelot X, Quan TP et al (2017) Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis 17:411\u2013421","journal-title":"Lancet Infect Dis"},{"key":"2622_CR8","unstructured":"European Centre for Disease Prevention and Control (2022a) Antimicrobial consumption in the EU\/EEA (ESAC-Net) - Annual Epidemiological Report 2021. Stockholm:"},{"key":"2622_CR9","unstructured":"European Centre for Disease Prevention and Control (2022b) Antimicrobial resistance in the EU\/EEA (EARS-Net) - Annual Epidemiological Report 2021. Stockholm.\u00a0https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER-EARS-Net-2021_2022-final.pdf"},{"key":"2622_CR10","doi-asserted-by":"publisher","unstructured":"European Centre for Disease Prevention and Control (2022c) Gonococcal antimicrobial susceptibility surveillance in the Europe Union\/European Economic Area. Summary of results 2020. Stockholm: ECDC. https:\/\/doi.org\/10.2900\/998412","DOI":"10.2900\/998412"},{"key":"2622_CR11","unstructured":"European Centre for Disease Prevention and Control (2023) Surveillance Atlas of Infectious Diseases. https:\/\/atlas.ecdc.europa.eu\/public\/index.aspx?Dataset=27&HealthTopic=21. Accessed 28 Feb 2023"},{"key":"2622_CR12","unstructured":"European Centre for Disease Prevention and Control WRO for E (2022) Tuberculosis surveillance and monitoring in Europe 2022 \u2013 2020 data. Copenhagen: WHO Regional Office for Europe and Stockholm: European Centre for Disease Prevention and Control"},{"key":"2622_CR13","unstructured":"European Medicines Agency (2019) Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/referral\/quinolone-fluoroquinolone-article-31-referraldisabling-potentially-permanent-side-effects-lead_en.pdf"},{"key":"2622_CR14","first-page":"35","volume":"3","author":"M Filip","year":"2017","unstructured":"Filip M (2017) Post\u0119powanie u doros\u0142ych chorych na szpitalne zapalenie p\u0142uc. Om\u00f3wienie wytycznych Infectious Diseases Society of America i American Thoracic Society 2016. Medycyna Praktyczna 3:35\u201350","journal-title":"Medycyna Praktyczna"},{"key":"2622_CR15","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1016\/S2666-5247(21)00005-7","volume":"2","author":"E Fortin","year":"2021","unstructured":"Fortin E, Thirion DJG, Ouakki M et al (2021) Role of high-risk antibiotic use in incidence of health-care-associated Clostridioides difficile infection in Quebec, Canada: a population-level ecological study. Lancet Microbe 2:e182\u2013e190","journal-title":"Lancet Microbe"},{"key":"2622_CR16","unstructured":"Geneva: World Health Organization (2019) Critically important antimicrobials for human medicine, 6th revision"},{"key":"2622_CR17","unstructured":"Geneva: World Health Organization (2020) WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment.\u00a0https:\/\/www.who.int\/publications\/i\/item\/9789240007048"},{"key":"2622_CR18","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1093\/ofid\/ofaa417.019","volume":"7","author":"KA Gouin","year":"2020","unstructured":"Gouin KA, King LM, Bartoces M, Roberts SKRM, Tsay S, Hicks L (2020) 20. Fluoroquinolone and Overall Outpatient Antibiotic Prescribing Trends in Adults, 2011 to 2018. Open Forum Infect Dis 7:S10\u2013S11","journal-title":"Open Forum Infect Dis"},{"key":"2622_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2011","unstructured":"Gupta K, Hooton TM, Naber KG et al (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:103\u2013120","journal-title":"Clin Infect Dis"},{"key":"2622_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025320","author":"DC Hooper","year":"2016","unstructured":"Hooper DC, Jacoby GA (2016) Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a025320","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2622_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/microorgamsms8060810","author":"E Jachowicz","year":"2020","unstructured":"Jachowicz E, Wa\u0142aszek M, Sulimka G, Maciejczak A, Zienczuk W, Ko\u0142odziej D, Karas J, Pobiega M, \u00d3jkowska-M Ach JW (2020) Long-term antibiotic prophylaxis in urology and high incidence of Clostridioides difficile infections in surgical adult patients. Microorganisms. https:\/\/doi.org\/10.3390\/microorgamsms8060810","journal-title":"Microorganisms"},{"key":"2622_CR22","unstructured":"Jan D, Drabczyk R (2022) Niepowik\u0142ane ostre odmiedniczkowe zapalenie nerek. In: Medycyna Praktyczna. https:\/\/www.mp.pl\/interna\/chapter\/B16.II.14.8.3. Accessed 13 Jun 2023"},{"key":"2622_CR23","first-page":"373","volume":"130","author":"E Jura\u0142owicz","year":"2020","unstructured":"Jura\u0142owicz E, Bartoszko-Tyczkowska A, Tyczkowska-Siero\u0144 E, Kurnatowska I (2020) Etiology and bacterial susceptibility to antibiotics in patients with recurrent lower urinary tract infections. Pol Arch Intern Med 130:373\u2013381","journal-title":"Pol Arch Intern Med"},{"key":"2622_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.arcmed.2020.06.004","volume":"51","author":"I Karampela","year":"2020","unstructured":"Karampela I, Dalamaga M (2020) Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19? Arch Med Res 51:741\u2013742","journal-title":"Arch Med Res"},{"key":"2622_CR25","first-page":"698","volume":"94","author":"A Kaysin","year":"2016","unstructured":"Kaysin A, Viera AJ (2016) Community-Acquired Pneumonia in Adults: Diagnosis and Management. Am Fam Physician 94:698\u2013706","journal-title":"Am Fam Physician"},{"key":"2622_CR26","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.46.2200845","author":"P Kinross","year":"2022","unstructured":"Kinross P, Gagliotti C, Merk H et al (2022) Large increase in bloodstream infections with carbapenem-resistant Acinetobacter species during the first 2 years of the COVID-19 pandemic, EU\/EEA, 2020 and 2021. Eurosurveillance. https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.46.2200845","journal-title":"Eurosurveillance"},{"key":"2622_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S1473-3099(16)30397-8","volume":"17","author":"T Lawes","year":"2017","unstructured":"Lawes T, Lopez-Lozano J-M, Nebot CA, Macartney G, Subbarao-Sharma R, Wares KD, Sinclair C, Gould IM (2017) Effect of a national 4C antibiotic stewardship intervention on the clinical and molecular epidemiology of Clostridium difficile infections in a region of Scotland: a non-linear time-series analysis. Lancet Infect Dis 17:194\u2013206","journal-title":"Lancet Infect Dis"},{"key":"2622_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa182","author":"K Lin","year":"2020","unstructured":"Lin K, Zahlanie Y, Ortwine JK, Mang NS, Wei W, Brown LS, Prokesch BC (2020) Decreased outpatient fluoroquinolone prescribing using a multimodal antimicrobial stewardship initiative. Open Forum Infect Dis. https:\/\/doi.org\/10.1093\/ofid\/ofaa182","journal-title":"Open Forum Infect Dis"},{"key":"2622_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jhin.2019.04.017","volume":"103","author":"A Maciejczak","year":"2019","unstructured":"Maciejczak A, Wolan-Nieroda A, Wa\u0142aszek M, Ko\u0142pa M, Wolak Z (2019) Antibiotic prophylaxis in spine surgery: a comparison of single-dose and 72-hour protocols. J Hosp Infect 103:303\u2013310","journal-title":"J Hosp Infect"},{"key":"2622_CR30","doi-asserted-by":"crossref","unstructured":"Markiewicz Z (2021) 1.1.1. Antybiotyki hamuj\u0105ce biosyntez\u0119 DNA. In: Markiewicz Z, Korsak D, Popowska M. Antybiotyki w dobie narastaj\u0105cej lekooporno\u015bci. Wydawnictwo Naukowe PWN, Warszawa, pp 45\u201348","DOI":"10.53271\/2021.013"},{"key":"2622_CR31","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.2147\/IDR.S319780","volume":"14","author":"BD Menz","year":"2021","unstructured":"Menz BD, Charani E, Gordon DL, Leather AJM, Ramani Moonesinghe S, Phillips CJ (2021) Surgical antibiotic prophylaxis in an era of antibiotic resistance: common resistant bacteria and wider considerations for practice. Infect Drug Resist 14:5235\u20135252","journal-title":"Infect Drug Resist"},{"key":"2622_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-65","author":"B Mlynarczyk-Bonikowska","year":"2014","unstructured":"Mlynarczyk-Bonikowska B, Serwin AB, Golparian D, Walter de Walthoffen S, Majewski S, Koper M, Malejczyk M, Domeika M, Unemo M (2014) Antimicrobial susceptibility\/resistance and genetic characteristics of Neisseria gonorrhoeae isolates from Poland, 2010\u20132012. BMC Infect Dis. https:\/\/doi.org\/10.1186\/1471-2334-14-65","journal-title":"BMC Infect Dis"},{"key":"2622_CR33","doi-asserted-by":"publisher","first-page":"764","DOI":"10.2471\/BLT.16.184374","volume":"95","author":"S M\u00f6lstad","year":"2017","unstructured":"M\u00f6lstad S, L\u00f6fmark S, Carlin K et al (2017) Lessons learnt during 20 years of the swedish strategic programme against antibiotic resistance. Bull World Health Organ 95:764\u2013773","journal-title":"Bull World Health Organ"},{"key":"2622_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21040268","author":"A Naeem","year":"2016","unstructured":"Naeem A, Badshah SL, Muska M, Ahmad N, Khan K (2016) The current case of quinolones: synthetic approaches and antibacterial activity. Molecules. https:\/\/doi.org\/10.3390\/molecules21040268","journal-title":"Molecules"},{"key":"2622_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jgar.2018.11.004","volume":"17","author":"S Ny","year":"2019","unstructured":"Ny S, Edquist P, Dumpis U et al (2019) Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia. J Glob Antimicrob Resist 17:25\u201334","journal-title":"J Glob Antimicrob Resist"},{"key":"2622_CR36","unstructured":"Pacurariu A, Flach C, Markov E, Lysen T, Ly N, Layton D (2019) Study of impact of EU label changes for fluoroquinolone containing medicinal products for systemic and inhalation use - post-referral prescribing trends.\u00a0https:\/\/www.encepp.eu\/encepp\/openAttachment\/studyResult\/48007"},{"key":"2622_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(22)00796-4","author":"J Patel","year":"2023","unstructured":"Patel J, Harant A, Fernandes G, Mwamelo AJ, Hein W, Dekker D, Sridhar D (2023) Measuring the global response to antimicrobial resistance, 2020\u201321: a systematic governance analysis of 114 countries. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/s1473-3099(22)00796-4","journal-title":"Lancet Infect Dis"},{"key":"2622_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.euf.2018.11.009","volume":"5","author":"A Pilatz","year":"2019","unstructured":"Pilatz A, Veeratterapillay R, K\u00f6ves B, Cai T, Bartoletti R, Wagenlehner F, Bruy\u00e8re F, Geerlings S, Bonkat G, Pradere B (2019) Update on strategies to reduce infectious complications after prostate biopsy. Eur Urol Focus 5:20\u201328","journal-title":"Eur Urol Focus"},{"key":"2622_CR39","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","volume":"372","author":"DF Postma","year":"2015","unstructured":"Postma DF, van Werkhoven CH, van Elden LJR et al (2015) Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 372:1312\u20131323","journal-title":"N Engl J Med"},{"key":"2622_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11070882","author":"OM Rostkowska","year":"2022","unstructured":"Rostkowska OM, Raczkiewicz D, Knap-Wielgus W, Zgliczy\u0144ski WS (2022) Polish medical doctors\u2019 opinions on available resources and information campaigns concerning antibiotics and antibiotic resistance, a cross-sectional study. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics11070882","journal-title":"Antibiotics"},{"key":"2622_CR41","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a017863","author":"KJ Seung","year":"2015","unstructured":"Seung KJ, Keshavjee S, Rich ML (2015) Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a017863","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2622_CR42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02313-16","author":"A Shah","year":"2017","unstructured":"Shah A, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN (2017) Application of fluoroquinolone resistance score in management of complicated urinary tract infections. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02313-16","journal-title":"Antimicrob Agents Chemother"},{"key":"2622_CR43","first-page":"587","volume":"66","author":"PC Sharma","year":"2009","unstructured":"Sharma PC, Jain A, Jain S (2009) Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm Drug Res 66:587\u2013604","journal-title":"Acta Pol Pharm Drug Res"},{"key":"2622_CR44","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.15585\/mmwr.mm6950a6","volume":"69","author":"S St Cyr","year":"2020","unstructured":"St Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, Torrone E, Weinstock H, Kersh EN, Thorpe P (2020) Update to CDC\u2019s Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep 69:1911\u20131916","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2622_CR45","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s10096-016-2673-1","volume":"35","author":"E Stefaniuk","year":"2016","unstructured":"Stefaniuk E, Suchocka U, Bosacka K, Hryniewicz W (2016) Etiology and antibiotic susceptibility of bacterial pathogens responsible for community-acquired urinary tract infections in Poland. Eur J Clin Microbiol Infect Dis 35:1363\u20131369","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2622_CR46","unstructured":"U.S. Food and Drug Administration (2016) FDA approves safety labeling changes for fluoroquinolones. https:\/\/www.fda.gov\/drugs\/information-drug-class\/fda-approves-safety-labeling-changes-fluoroquinolones. Accessed 27 Apr 2023"},{"key":"2622_CR47","unstructured":"U.S. Food and Drug Administration (2018a) FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics. Accessed 27 Apr 2023"},{"key":"2622_CR48","unstructured":"U.S. Food and Drug Administration (2018b) FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side. Accessed 27 Apr 2023"},{"key":"2622_CR49","unstructured":"U.S. Food and Drug Administration (2018c) FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics. Accessed 27 Apr 2023"},{"key":"2622_CR50","doi-asserted-by":"crossref","unstructured":"Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA (2021) Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 70:1\u2013187","DOI":"10.15585\/mmwr.rr7004a1"},{"key":"2622_CR51","unstructured":"Waleria H, Agnieszka Z (2020) Rekomendacje diagnostyki, terapii i profilaktyki antybiotykowej zaka\u017ce\u0144 w szpitalu - 2020: materia\u0142 przeznaczony dla komitet\u00f3w terapeutycznych i zespo\u0142\u00f3w ds. antybiotykoterapii polskich szpitali. Narodowy Instytut Lek\u00f3w"},{"key":"2622_CR52","unstructured":"WHO Regional Office for Europe\/European Centre for Disease Prevention and Control (2022) Antimicrobial resistance surveillance in Europe 2022 \u2013 2020 data. WHO Regional Office for Europe, Copenhagen"},{"key":"2622_CR53","unstructured":"World Health Organization (2016) WHO guidelines for the treatment of Neisseria gonorrhoeae.\u00a0https:\/\/www.who.int\/publications\/i\/item\/9789241549691"},{"key":"2622_CR54","unstructured":"World Health Organization (2023) Defined Daily Dose (DDD). https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/about-ddd. Accessed 28 Feb 2023"},{"key":"2622_CR55","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jiph.2018.02.003","volume":"11","author":"G Zi\u00f3\u0142kowski","year":"2018","unstructured":"Zi\u00f3\u0142kowski G, Paw\u0142owska I, Krawczyk L, Wojkowska-Mach J (2018) Antibiotic consumption versus the prevalence of multidrug-resistant Acinetobacter baumannii and Clostridium difficile infections at an ICU from 2014\u20132015. J Infect Public Health 11:626\u2013630","journal-title":"J Infect Public Health"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02622-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-023-02622-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02622-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T20:03:15Z","timestamp":1705435395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-023-02622-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2622"],"URL":"https:\/\/doi.org\/10.1007\/s00210-023-02622-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"14 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}